How big is the Neuromyelitis Optica Spectrum Disorder Market?

The Neuromyelitis Optica Spectrum Disorder Market size is expected to reach USD 592.17 million in 2024 and grow at a CAGR of 6.31% to reach USD 804.22 million by 2029. Read More

What is the current Neuromyelitis Optica Spectrum Disorder Market size?

In 2024, the Neuromyelitis Optica Spectrum Disorder Market size is expected to reach USD 592.17 million. Read More

Who are the key players in Neuromyelitis Optica Spectrum Disorder Market?

Hoffmann-La Roche Ltd, TG Therapeutics, Opexa Therapeutics, Mitsubishi Tanabe Pharma and Horizon Therapeutics plc (Viela Bio) are the major companies operating in the Neuromyelitis Optica Spectrum Disorder Market. Read More

Which is the fastest growing region in Neuromyelitis Optica Spectrum Disorder Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Neuromyelitis Optica Spectrum Disorder Market?

In 2024, the North America accounts for the largest market share in Neuromyelitis Optica Spectrum Disorder Market. Read More

What years does this Neuromyelitis Optica Spectrum Disorder Market cover, and what was the market size in 2023?

In 2023, the Neuromyelitis Optica Spectrum Disorder Market size was estimated at USD 554.80 million. The report covers the Neuromyelitis Optica Spectrum Disorder Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Neuromyelitis Optica Spectrum Disorder Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Neuromyelitis Optica Spectrum Disorder Market Share

Statistics for the 2023 & 2024 Neuromyelitis Optica Spectrum Disorder market share, created by Mordor Intelligence™ Industry Reports. Neuromyelitis Optica Spectrum Disorder share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Neuromyelitis Optica Spectrum Disorder Industry

The neuromyelitis optica spectrum disorder market is semi-consolidated, with many major players operating in it. Companies are focusing on adopting various business strategies such as collaborations, acquisitions, and product approvals to maintain their market position. Key players in this market include Hoffmann-La Roche Ltd, Horizon Therapeutics PLC, TG Therapeutics, Opexa Therapeutics, and Mitsubishi Tanabe Pharma.